FDA Panel Backs Grail Cancer Screening Test
An advisory panel to the U.S. Food and Drug Administration has concluded that the benefits of Grail’s Galleri blood test outweigh its risks for adults aged 50 and older. The 7-2 vote, with one abstention, is an important…
United States